首页> Oncoimmunology.> Efficacy and safety of immune checkpoint inhibitors in patients with advanced non–small cell lung cancer (NSCLC): a systematic literature review

Efficacy and safety of immune checkpoint inhibitors in patients with advanced non–small cell lung cancer (NSCLC): a systematic literature review

导出原文传递

翻译打印收藏纠错

第一作者： Wagner

作者： Wagner ^[1] ; Stollenwerk ; H.K. ; Klerings ; I. ; Pecherstorfer ; M. ; Gartlehner ; G. ; Singer ; J.

作者单位： Department for Evidence-based Medicine and Evaluation, Danube University Krems, Krems, Austria ^[1]

关键词 advanced non-small cell lung cancer Immune checkpoint inhibitors meta-analysis nsclc pd-1 pd-L1 systematic review

发布时间 2021-07-24

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览4

Oncoimmunology.

2020年9卷1期

art. no. 1774314-art. no. 1774314页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览4

Oncoimmunology.

2020年9卷1期

art. no. 1774314-art. no. 1774314页

检索历史清除

Efficacy and safety of immune checkpoint inhibitors in patients with advanced non–small cell lung cancer (NSCLC): a systematic literature review

Oncoimmunology.

相似文献

同项目论文

Oncoimmunology.

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Efficacy and safety of immune checkpoint inhibitors in patients with advanced non–small cell lung cancer (NSCLC): a systematic literature review

Oncoimmunology.

相似文献

同项目论文

Oncoimmunology.

相关期刊

检索历史清除